

June 4, 2024

Web Announcement 3370

## **Nevada Medicaid Updates Reimbursement of Commercial NDC-Labeled Paxlovid®**

Nevada Medicaid has updated reimbursement of commercial NDC-labeled Paxlovid® to reimburse pharmacies the ingredient cost in-addition to standard dispense fee. Please refer to section 10.0 of Pharmacy Manual for information on provider reimbursement.

Pharmacies may re-bill claims for commercial NDC-labeled Paxlovid® with date of service (DOS) on or after 11/01/2023 to receive updated reimbursement. For instructions on re-billing claims, pharmacies should refer to Section 3.3.1 of the Pharmacy Manual titled *Supported POS Transaction Types*.

Link to [Nevada Medicaid and Nevada Check Up Pharmacy Manual](#)

See [FDA announcement](#) for full information on Paxlovid® authorization and availability